Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
KPTI
KPTI
Nasdaq
Health Technology
Pharmaceuticals: Major
6.98
USD
-0.2
-2.79%
Buka: 07-23 14:42 (UTC+0)

KPTI Statistik Utama

Tinggi
7.16
Buka
7.14
Volume
147.89K
Rendah
6.88
Cierre anterior
7.18
Nilai Perdagangan
1.03M
Tertinggi 52M
10.99
Volume relatif
0.227
Amplitudo (%)
3.83%
Terendah 52M
3.65
Tingkat Perputaran
0.65%
Kap Pasar
162.71M
P/E (TTM)
--
P/E (Tahunan)
--
P/B
-0.61
P/S
1.08
Laba per Saham (EPS)
-15.087
Dividen (TTM)
0
Imbal Hasil Dividen
0.00%
Saham beredar
22.66M
Mata uang
USD

KPTI Kinerja Harga

7 hari
30 hari
90 hari
180 hari
Sejak awal tahun
1 Tahun
KPTI Distribusi Arus Dana
KPTI Volume Short Sale Harian
KPTI Riwayat Short Interest
As of 2026-07-23, the Karyopharm Therapeutics Inc. (KPTI) stock price today is 6.98. Based on this price, the company has a market capitalization of $162.71M, with a P/E ratio of --. On 2026-07-23, KPTI traded between 6.88 and 7.16. Today’s stock price is 1.45% above the daily low and 2.51% below the daily high, placing KPTI di kisaran bawah its most recent trading range. Trading volume currently stands at 147.89K, compared with an average daily volume of 652.77K. This suggests that trading activity is jauh di bawah level biasanya than usual. Over the past year, Karyopharm Therapeutics Inc. shares have traded between 3.65 and 10.99. At today’s price, KPTI is 91.23% above its 52-week low and 36.49% below its 52-week high.
Nama Perusahaan
Karyopharm Therapeutics Inc.
Sektor
Health Technology
Industri
Pharmaceuticals: Major
Bursa
Nasdaq
Jumlah Karyawan
228
Ukuran Lot
100
Mata uang
USD
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

KPTI FAQ

Cari
Lebih